This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon, France: International Agency for Research on Cancer, 2008.SwerdlowSHCampoEHarrisNLJaffeESPileriSASteinHet alWHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edLyon, FranceInternational Agency for Research on Cancer2008Search in Google Scholar
Rumi E, Pietra D, Pascutto C, Guglielmelli P, Martinez-Trillos A, Casetti I, et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood. 2014; 124(7): 1062-1069.10.1182/blood-2014-05-57843524986690RumiEPietraDPascuttoCGuglielmelliPMartinez-TrillosACasettiIet alClinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosisBlood2014124710621069Open DOISearch in Google Scholar
Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. Ν Engl J Med. 2013; 369(25): 2379-2390.10.1056/NEJMoa1311347KlampflTGisslingerHHarutyunyanASNivarthiHRumiEMilosevicJDet alSomatic mutations of calreticulin in myeloproliferative neoplasmsΝ Engl J Med20133692523792390Open DOISearch in Google Scholar
Cazzola M, Kralovics R. From Janus kinase 2 to calreticulin: The clinically relevant genomic landscape of myeloproliferative neoplasms. Blood. 2014; 123(24): 3714-3719.10.1182/blood-2014-03-53086524786775CazzolaMKralovicsRFrom Janus kinase 2 to calreticulin: The clinically relevant genomic landscape of myeloproliferative neoplasmsBlood20141232437143719Open DOISearch in Google Scholar
Ha JS, Kim YK. Calreticulin exon 9 mutations in myeloproliferative neoplasms. Ann Lab Med. 2015; 35(1): 22-27.10.3343/alm.2015.35.1.2225553276HaJSKimYKCalreticulin exon 9 mutations in myeloproliferative neoplasmsAnn Lab Med20153512227Open DOISearch in Google Scholar
Lavi N. Calreticulin mutations in myeloproliferative neoplasms. Rambam Maimonides Med J. 2014; 5(4): e0035.10.5041/RMMJ.1016925386351LaviNCalreticulin mutations in myeloproliferative neoplasmsRambam Maimonides Med J201454e0035Open DOISearch in Google Scholar
Montoro J, Robledo C, Zamora L, Valcarcel D, Ramos F. Calreticulin mutations are exceedingly rare in patients with myelodysplastic syndromes with myelofibrosis. Ann Hematol. 2017; 96(2): 317-318.2773034310.1007/s00277-016-2849-xMontoroJRobledoCZamoraLValcarcelDRamosFCalreticulin mutations are exceedingly rare in patients with myelodysplastic syndromes with myelofibrosisAnn Hematol2017962317318Search in Google Scholar
Ebid GT, Ghareeb M, Salaheldin O, Kamel MM. Prevalence of the frequency of JAK2 (V617F) mutation in different myeloproliferative disorders in Egyptian patients. Int J Clin Exp Pathol. 2015; 8(9): 11555-11559.26617890EbidGTGhareebMSalaheldinOKamelMMPrevalence of the frequency of JAK2 (V617F) mutation in different myeloproliferative disorders in Egyptian patientsInt J Clin Exp Pathol2015891155511559Search in Google Scholar
Passamonti F, Maffioli M, Caramazza D, Cazzola M. Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies. Oncotarget. 2011; 2(6): 485-490.21646683PassamontiFMaffioliMCaramazzaDCazzolaMMyeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapiesOncotarget20112648549010.18632/oncotarget.281Search in Google Scholar
de Freitas RM, da Costa Maranduba CM. Myelo-proliferative neoplasms and the JAK/STAT signaling pathway: An overview. Rev Bras Hematol Hemoter. 2015; 37(5): 348-353.10.1016/j.bjhh.2014.10.001deFreitas RMdaCosta Maranduba CMMyelo-proliferative neoplasms and the JAK/STAT signaling pathway: An overviewRev Bras Hematol Hemoter2015375348353Open DOISearch in Google Scholar
Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: A prospective study. Lancet. 2005; 366(9501): 1945-1953.10.1016/S0140-6736(05)67785-916325696CampbellPJScottLMBuckGWheatleyKEastCLMarsdenJTet alDefinition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: A prospective studyLancet2005366950119451953Open DOISearch in Google Scholar
Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentīni Μ, et al. Life expectancy and prognostic factors for survival in patients with poly-cythemia vera and essential thrombocythemia. Am J Med. 2004; 117(10): 755-761.10.1016/j.amjmed.2004.06.032PassamontiFRumiEPungolinoEMalabarbaLBertazzoniPValentīniΜet alLife expectancy and prognostic factors for survival in patients with poly-cythemia vera and essential thrombocythemiaAm J Med20041171075576115541325Open DOISearch in Google Scholar
Baxter ΕJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005; 365(9464): 1054-1061.10.1016/S0140-6736(05)71142-915781101BaxterΕJScottLMCampbellPJEastCFourouclasNSwantonSet alAcquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disordersLancet2005365946410541061Open DOISearch in Google Scholar
Lichtman M, Beutler E. Idiopathic myelofibrosis (agnogenic myeloid metaplasia). In: Beutler E, Editor. William's Hematology. New York, NY, USA: McGraw-Hill. 2001: 1125-1136.LichtmanMBeutlerEIdiopathic myelofibrosis (agnogenic myeloid metaplasia)BeutlerEWilliam's HematologyNew York, NY, USAMcGraw-Hill200111251136Search in Google Scholar
Mavroudis D, Barrett B. Myelofibrosis (agnogenic myeloid metaplasia). In: Young N, Editor. Bone Marrow Failure Syndrome. Philadelphia, PA, USA: W.B. Saunders Company. 2000: 122-134.MavroudisDBarrettBMyelofibrosis (agnogenic myeloid metaplasia)YoungNBone Marrow Failure SyndromePhiladelphia, PA, USAW.B. Saunders Company2000122134Search in Google Scholar
Peterson P. Myelofibrosis. In: Kjeldsberg C, Editor. Myelofibrosis. Practical Diagnosis of Hematologic Disorders. Chicago, IL, USA: American Society for Clinical Pathology Press. 2010: 477-479.PetersonPMyelofibrosisKjeldsbergCMyelofibrosis. Practical Diagnosis of Hematologic DisordersChicago, IL, USAAmerican Society for Clinical Pathology Press2010477479Search in Google Scholar
Rego de Paula Μ Jr, Nonino A, Minuncio Nascimento J, Bonadio RS, Pic-Taylor A, de Oliveira SF, et al. High frequency of copy-neutral loss of heterozygosity in patients with myelofibrosis. Cytogenet Genome Res. 2018; 154(2):62-70.2958726110.1159/000487627Regode Paula Μ JrNoninoAMinuncioNascimento JBonadioRSPic-TaylorAdeOliveira SFet alHigh frequency of copy-neutral loss of heterozygosity in patients with myelofibrosisCytogenet Genome Res20181542627029587261Search in Google Scholar
Cottin L, Riou J, Boyer F, Bouvier A, Zannetti A, Blouet A, et al. WT1 gene is overexpressed in myeloproliferative neoplasms, especially in myelofibrosis. Blood Cells Mol Dis. 2019; 75: 35-40.10.1016/j.bcmd.2018.12.00430612065CottinLRiouJBoyerFBouvierAZannettiABlouetAet alWT1 gene is overexpressed in myeloproliferative neoplasms, especially in myelofibrosisBlood Cells Mol Dis201975354030612065Open DOISearch in Google Scholar
O'Sullivan J, Mead AJ. Heterogeneity in myeloproliferative neoplasms: Causes and consequences. Adv Biol Regul. 2019; 71: 55-68.10.1016/j.jbior.2018.11.00730528537O'SullivanJMeadAJHeterogeneity in myeloproliferative neoplasms: Causes and consequencesAdv Biol Regul201971556830528537Open DOISearch in Google Scholar
Takenaka K, Shimoda K, Akashi K. Recent advances in the diagnosis and management of primary myelofibrosis. Korean J Intern Med. 2018; 33(4): 679-690.10.3904/kjim.2018.03329665657TakenakaKShimodaKAkashiKRecent advances in the diagnosis and management of primary myelofibrosisKorean J Intern Med2018334679690603041229665657Open DOISearch in Google Scholar
